[go: up one dir, main page]

HUP9901628A2 - Eljárások és készítmények alfa v béta5-közvetítette angiogenezis gátlására - Google Patents

Eljárások és készítmények alfa v béta5-közvetítette angiogenezis gátlására

Info

Publication number
HUP9901628A2
HUP9901628A2 HU9901628A HUP9901628A HUP9901628A2 HU P9901628 A2 HUP9901628 A2 HU P9901628A2 HU 9901628 A HU9901628 A HU 9901628A HU P9901628 A HUP9901628 A HU P9901628A HU P9901628 A2 HUP9901628 A2 HU P9901628A2
Authority
HU
Hungary
Prior art keywords
inhibiting
beta5
alfa
inhibition
methods
Prior art date
Application number
HU9901628A
Other languages
English (en)
Inventor
Peter Brooks
David A. Cheresh
Martin Friedlander
Original Assignee
The Scripps Research Institute
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Scripps Research Institute filed Critical The Scripps Research Institute
Publication of HUP9901628A2 publication Critical patent/HUP9901628A2/hu
Publication of HUP9901628A3 publication Critical patent/HUP9901628A3/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6489—Metalloendopeptidases (3.4.24)
    • C12N9/6491—Matrix metalloproteases [MMP's], e.g. interstitial collagenase (3.4.24.7); Stromelysins (3.4.24.17; 3.2.1.22); Matrilysin (3.4.24.23)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C279/00—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups
    • C07C279/04—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of guanidine groups bound to acyclic carbon atoms of a carbon skeleton
    • C07C279/14—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of guanidine groups bound to acyclic carbon atoms of a carbon skeleton being further substituted by carboxyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/01—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms
    • C07C311/02—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C311/03—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atoms of the sulfonamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C311/06—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atoms of the sulfonamide groups bound to hydrogen atoms or to acyclic carbon atoms to acyclic carbon atoms of hydrocarbon radicals substituted by carboxyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/01—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms
    • C07C311/10—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of a saturated carbon skeleton containing rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/34—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D263/36—One oxygen atom
    • C07D263/38—One oxygen atom attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/75—Fibrinogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • C07K16/2848—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta3-subunit-containing molecules, e.g. CD41, CD51, CD61
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/36—Systems containing two condensed rings the rings having more than two atoms in common
    • C07C2602/42—Systems containing two condensed rings the rings having more than two atoms in common the bicyclo ring system containing seven carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Wood Science & Technology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Microbiology (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Toxicology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biotechnology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

A találmány tárgyát őlyan készítmények képezik, amelyek - az avb5elnevezésű vitrőnektin-receptőr antagőnistáinak alkalmazásával -szövetek angiőgenezisének gátlására alkalmazhatók. Szintén a találmánytárgyát képezik az avb5-antagőnisták - különféle szövetekben lezajlóangiőgenezis gátlására irányűló - eljárásőkban történő alkalmazásai. Atalálmány szerinti megőldás alkalmas új erek nem kívánatős (pl.gyűlladásős szövetekben, tűmőrőkban vagy metasztázisőkban, illetveretinaszövetben bekövetkező ) képződésének gátlására, a tűmőrnöve-kedés gátlására, metasztázisők kialakűlásának gátlására, valamint márkialakűlt tűmőrők visszafejlesztésére. ŕ
HU9901628A 1996-05-31 1997-05-30 Methods and compositions useful for inhibition of alfa v beta5 mediated angiogenesis HUP9901628A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US1586996P 1996-05-31 1996-05-31
US1873396P 1996-05-31 1996-05-31

Publications (2)

Publication Number Publication Date
HUP9901628A2 true HUP9901628A2 (hu) 1999-08-30
HUP9901628A3 HUP9901628A3 (en) 2002-11-28

Family

ID=26687899

Family Applications (2)

Application Number Title Priority Date Filing Date
HU9902099A HUP9902099A3 (en) 1996-05-31 1997-05-30 Methods and compositions useful for inhibition of angiogenesis
HU9901628A HUP9901628A3 (en) 1996-05-31 1997-05-30 Methods and compositions useful for inhibition of alfa v beta5 mediated angiogenesis

Family Applications Before (1)

Application Number Title Priority Date Filing Date
HU9902099A HUP9902099A3 (en) 1996-05-31 1997-05-30 Methods and compositions useful for inhibition of angiogenesis

Country Status (14)

Country Link
EP (2) EP0907661A4 (hu)
JP (1) JP2002515036A (hu)
KR (2) KR20000016301A (hu)
CN (1) CN1226254A (hu)
AT (1) ATE470450T1 (hu)
BR (1) BR9709514A (hu)
CA (2) CA2256588A1 (hu)
CZ (2) CZ380098A3 (hu)
DE (1) DE69739907D1 (hu)
DK (1) DK0951295T3 (hu)
HU (2) HUP9902099A3 (hu)
NO (2) NO985574L (hu)
PL (2) PL330241A1 (hu)
WO (2) WO1997045447A1 (hu)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040063790A1 (en) * 1996-05-31 2004-04-01 The Scripps Research Institute Methods for inhibition of angiogenesis
US7387779B2 (en) 1998-06-17 2008-06-17 Beth Israel Deaconess Medical Center Anti-angiogenic proteins and fragments and methods of use thereof
US6962974B1 (en) 1998-06-17 2005-11-08 Beth Israel Deaconess Medical Center Anti-angiogenic proteins and fragments and methods of use thereof
US6759047B1 (en) 1998-06-17 2004-07-06 Beth Israel Deaconess Hospital Corp. Anti-angiogenic proteins and methods of use thereof
AU740781B2 (en) 1998-07-14 2001-11-15 Pharmacia & Upjohn Company Oxazolidinones to treat eye infections
DE19842415A1 (de) * 1998-09-16 2000-03-23 Merck Patent Gmbh Pharmazeutische Zubereitung
US6521593B1 (en) * 1999-02-01 2003-02-18 Childrens Hospital Los Angeles Methods for inhibiting brain tumor growth
US6344484B1 (en) 1999-02-12 2002-02-05 3-Dimensional Pharmaceuticals, Inc. Tyrosine alkoxyguanidines as integrin inhibitors
PT1156823E (pt) 1999-02-12 2009-01-08 Scripps Research Inst Métodos para tratamento de tumores e metástases utilizando uma combinação de terapias anti-angiogénicas e imunitárias
UA71608C2 (en) * 1999-03-11 2004-12-15 Merck Patent Gmbh A method for producing the cyclic pentapeptide
JP2003534558A (ja) * 2000-05-26 2003-11-18 グラクソ グループ リミテッド ＬＡＰ（潜在型結合ペプチド）とインテグリンαｖβ３との間の相互作用のモジュレーターを同定する方法及びその医学的使用
CN1329167A (zh) * 2000-06-19 2002-01-02 上海博德基因开发有限公司 一种新的多肽——人非整合蛋白－金属蛋白酶10.67和编码这种多肽的多核苷酸
US6486174B2 (en) 2000-08-07 2002-11-26 3-Dimensional Pharmaceuticals, Inc. Tetrahydroisoquinoline-3-carboxylic acid alkoxyguanidines as integrin antagonists
ATE415163T1 (de) 2000-11-01 2008-12-15 Merck Patent Gmbh Verfahren und zusammensetzungen zur behandlung von augenerkrankungen
MXPA03006772A (es) 2001-01-29 2004-10-15 Dimensional Pharm Inc Indoles sustituidos y su uso como antogonistas de integrina.
WO2002085405A2 (en) 2001-04-24 2002-10-31 Merck Patent Gmbh COMBINATION THERAPY USING ANTI-ANGIOGENIC AGENTS AND TNF$g(a)
US6872730B2 (en) 2001-04-27 2005-03-29 3-Dimensional Pharmaceuticals, Inc. Substituted benzofurans and benzothiophenes, methods of making and methods of use as integrin antagonists
US7019108B2 (en) * 2001-06-01 2006-03-28 University Of Southern California Method and composition for inhibition of angiogenesis and tumor growth using compounds based on a sequence within MMP-2
KR20040028966A (ko) * 2001-08-01 2004-04-03 메르크 파텐트 게엠베하 안구 질환 치료용 인테그린 억제제
DE10159453A1 (de) * 2001-12-04 2003-06-18 Merck Patent Gmbh Verwendung von 1-Phenyl-oxazolidin-2-on-Verbindungen als Protease
GB0217017D0 (en) * 2002-07-23 2002-08-28 Bioacta Ltd Peptide 2
FR2856598B1 (fr) 2003-06-25 2005-10-28 Inst Nat Sante Rech Med Peptides derives de la proteine mmp-2 et leur utilisation en immunotherapie antitumorale
US7196061B2 (en) * 2003-09-10 2007-03-27 Wyeth Compounds that modulate neuronal growth and their uses
WO2007084670A2 (en) 2006-01-18 2007-07-26 Merck Patent Gmbh Specific therapy using integrin ligands for treating cancer
EP1862541A1 (en) * 2006-06-01 2007-12-05 Institut National De La Sante Et De La Recherche Medicale (Inserm) Polypeptides derived from the hemopexin-like domain of metalloproteinase MMP-2
PL2101805T3 (pl) 2007-01-18 2013-04-30 Merck Patent Gmbh Ligandy integryn do stosowania w leczeniu nowotworów
US20110243927A1 (en) * 2007-08-24 2011-10-06 University Health Network Methods of inhibiting tumor growth using beta 5 integrin antagonists
EP2990487A1 (en) 2008-05-08 2016-03-02 Asuragen, INC. Compositions and methods related to mirna modulation of neovascularization or angiogenesis
SG176103A1 (en) 2009-05-25 2011-12-29 Merck Patent Gmbh Continuous administration of cilengitide in cancer treatments
KR101988362B1 (ko) * 2009-11-10 2019-06-12 알레그로 파마슈티칼스, 인코포레이티드. Ｒｇｄ 바인딩 부위에 대한 세포 부착의 저해 또는 진단제 또는 치료제의 유도를 위한 조성물 및 방법
US11673914B2 (en) 2009-11-10 2023-06-13 Allegro Pharmaceuticals, LLC Peptide therapies for reduction of macular thickening
WO2014163156A1 (ja) 2013-04-04 2014-10-09 味の素株式会社 脱保護方法
US20170362324A1 (en) * 2014-09-12 2017-12-21 Biogen Ma Inc. Humanized anti-alpha v beta 5 antibodies and uses thereof
CN111748041B (zh) * 2019-03-11 2021-09-14 中国科学院苏州纳米技术与纳米仿生研究所 微环境控释型功能化水凝胶、其制备方法及应用
CN116239704B (zh) * 2023-05-09 2023-07-14 北京青云智创科技有限公司 一种治疗新生血管性眼病的多肽及其制剂

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5770565A (en) * 1994-04-13 1998-06-23 La Jolla Cancer Research Center Peptides for reducing or inhibiting bone resorption
CA2754102C (en) * 1995-08-14 2012-12-18 The Scripps Research Institute Monoclonal antibodies and compositions comprising such useful for inhibition of .alpha.v.beta.5 mediated angiogenesis
DE19534177A1 (de) * 1995-09-15 1997-03-20 Merck Patent Gmbh Cyclische Adhäsionsinhibitoren
DE19538741A1 (de) * 1995-10-18 1997-04-24 Merck Patent Gmbh Cyclopeptidderivate

Also Published As

Publication number Publication date
CA2256588A1 (en) 1997-12-04
KR20000016301A (ko) 2000-03-25
KR20000016302A (ko) 2000-03-25
NO985574L (no) 1999-02-01
WO1997045137A8 (en) 2001-02-01
DK0951295T3 (da) 2010-09-13
PL330241A1 (en) 1999-05-10
WO1997045447A1 (en) 1997-12-04
CZ380098A3 (cs) 1999-05-12
DE69739907D1 (de) 2010-07-22
HUP9902099A3 (en) 2001-10-29
PL330240A1 (en) 1999-05-10
NO985575D0 (no) 1998-11-27
EP0907661A1 (en) 1999-04-14
CA2256543C (en) 2010-12-07
CZ383498A3 (cs) 1999-05-12
HUP9901628A3 (en) 2002-11-28
WO1997045137A1 (en) 1997-12-04
CN1226254A (zh) 1999-08-18
BR9709514A (pt) 1999-08-10
ATE470450T1 (de) 2010-06-15
NO985575L (no) 1999-02-01
EP0907661A4 (en) 2000-07-26
HUP9902099A2 (hu) 1999-09-28
EP0951295A4 (en) 2000-07-26
JP2002515036A (ja) 2002-05-21
EP0951295A1 (en) 1999-10-27
CA2256543A1 (en) 1997-12-04
EP0951295B1 (en) 2010-06-09
NO985574D0 (no) 1998-11-27

Similar Documents

Publication Publication Date Title
HUP9901628A2 (hu) Eljárások és készítmények alfa v béta5-közvetítette angiogenezis gátlására
MY134783A (en) Rho-kinase inhibitors
WO2002076977A3 (en) Rho-kinase inhibitors
DE60043229D1 (de) Zusammensetzung zur gefässbeschichtung
ATE444960T1 (de) Polyhydroxystilbene und -stilbenoxide als antipsoriasismittel und proteinkinasehemmer
YU97902A (sh) Ciklopentanoindoli, smeše koje sadrže takva jedinjenja i metodi lečenja
HUP9902092A2 (hu) Metalloproteináz gátló benzolszulfonamidszármazékok, intermedierjeik, előállításuk és alkalmazásuk, a vegyületeket tartalmazó gyógyászati készítmények
MXPA05003273A (es) Procedimiento para preparar inhibidores de quinazolina rho-cinasa e intermediarios de los mismos.
HK1087700A1 (en) Triazolopyridazines as protein kinases inhibitors
FI880464A0 (fi) Bekaempningsmedel mot tandplaque och -karies.
BG66087B1 (bg) Хинолинонови производни като тирозин киназни инхибитори
WO2005065242A3 (en) Method of treating cancer using platelet releasate
DE69937888D1 (de) Verbesserung der herzfunktion durch transplantation mesenchymaler stammzellen
EA200300845A1 (ru) Модифицированные антитела и способы применения
MY146669A (en) Pyrazole derivatives for treating hiv
TW200613306A (en) Imidazotriazines as protein kinase inhibitors
DK0813525T3 (da) Benzamidinderivater, deres fremstilling og anvendelse som antikoagulanter
MD970253A (ro) Inhibitori biciclici micromoleculari ai trombinei
HUP0101137A2 (hu) Véralvadást gátló savamidin-származékok és gyógyászati alkalmazásuk
NO20010203L (no) Diacylhydrazinderivater som integrininhibitorer
BR0011272A (pt) Piridonas de heteroarila e arila policìclica substituìdas úteis para a inibição seletiva da cascata de coagulação
DE60230155D1 (de) Verwendung von verzweigtkettigen fettsäuren und ihrer derivate zur schmerzbehandlung
PT1294874E (pt) Variantes de cd154 e as suas utilizacoes
CA2416879A1 (en) Methods of treating cancer and the pain associated therewith using endothelin antagonists
AUPP345098A0 (en) Novel anti-fibrinolytic agents